iCo Therapeutics Sidesteps VEGF in Diabetic Macular Edema

iCo Therapeutics – Andrew Rae, President & CEO for iCo Therapeutics, shares the company’s focus on diabetic macular edema and their 187 patient study, which is fully enrolled in the U.S. Viewing an opportunity to better serve this population, ICO Therapeutics talks about their products that provide improved outcomes for patients not responding or only partially responding to the widely used VEGF treatments.


Andrew Rae

Andrew Rae

Mr. Rae is President and CEO of iCo Therapeutics, Inc., an ocular development company he co-founded in 2005.

View Full Profile